FTC agrees to re-open Actavis and Watson merger decision

The Federal Trade Commission (FTC) has approved an application by pharmaceutical company Teva to re-open and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

FTC launches pharma merger analysis group

18 March 2021 The Federal Trade Commission (FTC) is launching a new international working group in an “imperative” move to better analyse the impact of pharmaceutical mergers.

Generics

Teva and FTC reach settlement over ‘pay-for-delay’

20 February 2019 Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.

Big Pharma

Teva settles Sensipar patent dispute with Amgen

4 January 2019 Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.

More on this story

Americas

FTC launches pharma merger analysis group

18 March 2021 The Federal Trade Commission (FTC) is launching a new international working group in an “imperative” move to better analyse the impact of pharmaceutical mergers.

Generics

Teva and FTC reach settlement over ‘pay-for-delay’

Big Pharma

Teva settles Sensipar patent dispute with Amgen

4 January 2019 Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.

More on this story

Americas

FTC launches pharma merger analysis group

18 March 2021 The Federal Trade Commission (FTC) is launching a new international working group in an “imperative” move to better analyse the impact of pharmaceutical mergers.

Generics

Teva and FTC reach settlement over ‘pay-for-delay’

Big Pharma

Teva settles Sensipar patent dispute with Amgen

4 January 2019 Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.